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Improved access to anti-retroviral therapy increases the need for affordable monitoring using assays such as CD4
and/or viral load in resource-limited settings. Barriers to accessing treatment, high rates of loss to initiation and poor
retention in care are prompting the need to find alternatives to conventional centralized laboratory testing in
certain countries. Strong advocacy has led to a rapidly expanding repertoire of point-of-care tests for HIV. point-of-
care testing is not without its challenges: poor regulatory control, lack of guidelines, absence of quality monitoring
and lack of industry standards for connectivity, to name a few. The management of HIV increasingly requires a
multidisciplinary testing approach involving hematology, chemistry, and tests associated with the management of
non-communicable diseases, thus added expertise is needed. This is further complicated by additional human
resource requirements and the need for continuous training, a sustainable supply chain, and reimbursement
strategies. It is clear that to ensure appropriate national implementation either in a tiered laboratory model or a
total decentralized model, clear country-specific assessments need to be conducted.
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Globally, the number of persons living with HIV has in-
creased from 34 million (31.4 to 35.9 million) in 2011 to
an estimated 35.3 million (32.2 to 38.8 million) in 2012;
approximately 69% of the global HIV burden resides in
sub-Saharan Africa [1]. In response to anti-retroviral
therapy (ART) programs, a concurrent drop in AIDS-
related deaths from 2.3 million (2.1 to 2.6 million) in
2005 to 1.6 million (1.4 to 1.9 million) in 2012 has been
recorded [1]. In order to reach the expected 2020
goals, a massive increase in HIV testing capacity will
be required.
The expansion of ART programs can only be des-
cribed as a huge success in low- and middle- income
countries. Estimates reached 9.7 million on ART at the
end of 2012, representing some 60% of those in need at
that time [2]. With the new World Health Organization
(WHO) guidelines changing the CD4 test threshold for* Correspondence: wendy.stevens@nhls.ac.za
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viduals infected with HIV potentially requiring access to
treatment has increased to an estimated 28.6 million [1].
Challenges to continued ART scale-up remain, and in-
clude improving access to HIV testing, ensuring universal
access to testing, earlier initiation of treatment by im-
proved access to HIV testing, ensuring subsequent linkage
to care, and finally long-term retention in care. Each phase
of HIV diagnosis and monitoring is supported by a num-
ber of tests conducted according to different algorithms in
many high-burden countries, each with human and tech-
nical resource requirements. HIV rapid tests, used in
adults in serial or parallel algorithms using one to three
different assays, have been instrumental in ensuring
wide-scale diagnosis and access to care, albeit with on-
going challenges to ensure quality. A recent estimate from
President's Emergency Plan for AIDS Relief (PEPFAR)
countries suggests over 80 million HIV rapid assays were
performed in 2013 and that 11% of all assays were
conducted as point-of-care tests (POCTs) (Jason Williams,
personal communication).
CD4 testing has been the gatekeeper for assessing im-
mune status and establishing eligibility for treatment and
care. Treatment eligibility threshold levels have changedl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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2010 [4]. More recently, the new consolidated WHO rec-
ommendations suggest initiation at CD4 counts of <500
cells/μl [5]. Further suggestions of universal access and
test and treat strategies are also being evaluated and hotly
debated [6]. The latter approach is already occurring
for certain high-risk population groups such as those
co-infected with tuberculosis (TB), pregnant women, and
children under 5 years of age. CD4 count has also been
used for regular monitoring of immunological recovery on
treatment, generally at six-monthly intervals. CD4 testing
can be done at different tiers of the laboratory service [7]
and the frequent delay in linking this assay to the initi-
ation of patient care can result in significant loss to
follow-up [8]. CD4 testing is also recommended by WHO
and used in South Africa as a benchmark for estab-
lishing the risk of cryptococcal infection, where testing for
cryptococcal antigen can now be done at point-of-care
(POC) and the onset of meningitis can be prevented if
treated with fluconazole [9].
The HIV viral load (VL) assay, a nucleic-acid-based
test, is used to monitor response to treatment; an unde-
tectable viral load defines treatment success. VL testing
is frequently done in centralized facilities and currently
requires expensive instrumentation, technical skill, and
has relatively high costs per assay. Despite these chal-
lenges, this assay has gained its rightful place in guide-
lines and clinical practice and is thought to be the most
reliable marker for treatment success [10,11]. The deve-
lopment pipeline of POC VL assays promises to deliver
a number of options to improve access and facilitate
earlier identification of treatment failure. This will allow
clinicians to avoid premature switching of regimens,
particularly in regions with limited drug availability, po-
tentially improving patient adherence and reducing the
development of drug resistance [12]. Also, the percent-
age of failures using this assay can provide a monitor of
both individual and program success [13]. As access to
VL testing is improving, the role of CD4 measurements
is being reassessed. Numerous studies have demon-
strated that for the vast majority of people living with
HIV who are receiving ART and are virally suppressed,
CD4 cell count does not decline over time [14]. Other
studies have shown that one third of individuals whose
CD4 count was greater than 350 cells/μl had viral loads
greater than 100,000 HIV RNA copies/ml [15]. A meta-
analysis of seven studies assessing the accuracy of clin-
ical or CD4 tests in predicting virological failure found a
poor sensitivity of 26.6% and a positive predictive value
of 49.4% [11]. This suggests that in situations where viral
load is available routinely, CD4 monitoring can be re-
duced in frequency or stopped altogether. Recognizing
this opportunity to save resources, the South African
ART guidelines in 2013 recommended stopping routineCD4 monitoring in people who are stable on ART and a
number of other countries are considering moving in
this direction [16].
In addition to the core assays described in individuals
with HIV, there are also hematology and biochemistry
assays that remain important, including hemoglobin,
creatinine (especially for tenofovir initiation) and liver
transaminase tests as well as assays for the diagnosis of
opportunistic infections such as TB and cryptococcal in-
fection. The diagnosis and treatment of TB is critical in
low- and middle- income countries where a significant
proportion of individuals with HIV infection are
co-infected with TB. In South Africa as an example,
co-infection rates are as high as 65% to 70% [17].
To address all the needs described above and in the
face of the successes of rapid tests such as those for
HIV, malaria and, more recently, cryptococcal antigen,
there is a drive now towards using POCT for the non-
communicable diseases such as diabetes, cardiovascular
disease and cancer, many of which are associated with
long-term management of people living with HIV. Thus,
there is an expanded list of multidisciplinary testing
needs at primary health clinics (PHC). Performing and
interpretation of these tests will potentially require
significantly more expertise than a single rapid HIV
antibody test.
History of point-of-care testing
POCT is an old approach to testing that has been around
for decades and remains as controversial today as it was
when first introduced. POCT refers to testing that is
performed near to or at the site of patient care, with the
result leading to a possible or immediate change to patient
care [18]. The rationale is largely based on a need for
shortening the time to decision making. The literature
provides a myriad of different definitions such as the
Clinical Laboratory Standards Institute in the USA, which
defines the purpose of POCT being the provision of timely
results that clinically and cost-effectively contribute to
management decisions [19]. The first references to POCT
date back to the early 1990s and focused largely on glu-
cose testing for diabetes and blood gas analyzers in ICUs
and operating theaters [20]. The controversy around man-
agerial, quality and regulatory ownership remains a prob-
lem and it has been suggested that this is still a ‘work in
progress’ [21]. Despite this, POCT is the fastest growing
segment of the diagnostic industry (10% to 14% annually),
accounting for one in four tests within the developing
world [22,23]. A recent review reported that POCT ac-
counts for 25% of total laboratory revenue [24]. New diag-
nostics into which POCT has expanded include cardiac
markers, coagulation assays, substance abuse and home-
based HIV testing, to name a few [25]. Interestingly, POC
devices include not only ex vitro but also in vitro and
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[26]. Technological advances such as microfluidics [27],
miniaturization [28], microfabrication, simple power and
affordable light sources, electromagnetic actuation of
fluids using microelectronics and, more recently, nano-
diagnostics [29,30] have facilitated the development of
more complex assays capable of placement at the POC
[28]. Thus, rapid tests described for HIV diagnosis have
been described as first-generation POC assays, involving
antigens and antibodies and simple biochemistry and
hematology; the second generation is infinitely more
complex and based on cell detection or nucleic acid
amplification and detection; the third generation will
involve complex analyzers that could have multiplexing
capabilities [31].
Global perspective on point-of-care testing
The unmet laboratory needs for assays to address com-
municable diseases such as HIV, TB and malaria appear
to have assisted in catalyzing the POC diagnostics industry
as a whole. Both communicable and non-communicable
diseases will in future reap the benefits as appropriate im-
plementation strategies are developed [31]. This is particu-
larly important when predictions for the future suggest
that diabetes may well be a more important risk factor for
TB than HIV. Global market assessments have suggested
that the increase in diabetes and thus glucose testing com-
prises at least 10% of the global POCT market [32]. The
growth in POC HIV testing has been further reinforced by
strong advocacy from groups such as the WHO (One
pillar of Treatment v2.0 {WHO Department of HIV/AIDS,
2011 #99}guideline [33], WHO 2013 treatment guide-
lines [34]), UNITAID (market catalysts; Geneva), the Bill
and Melinda Gates Foundation, the Clinton Foundation,
PEPFAR and the African Society of Laboratory Medicine,
who have been tasked with promoting guidance and im-
plementation in field sites. This drive has begun to address
many of the factors mentioned above, such as the absence
of laboratories or access to assays such as CD4 and VL
testing for the diagnosis and monitoring of HIV in remote
sites. Alternatives to conventional centralized testing are
being driven by the high rates of loss to initiation for both
HIV and TB, as well poor retention in care [35]. These
activities have catalyzed funders, suppliers, users and
patients in galvanizing the POC diagnostics industry into
action. In addition, POCT has been incorporated into the
Global Health Strategy on HIV/AIDS [36]. Both the
WHO and the London School of Tropical Medicine
and Hygiene have been tasked with bringing forward
multi-center laboratory-based validations of POC assays
followed by an evaluation of their implementation in the
field [37]. Strong emphasis has also been placed on the
need for monitoring the impact and cost of the interven-
tions across the entire continuum of care. By nature of thelow throughput of these technologies and the additional
human resources required in the field for testing and
maintenance, the total assay costs can be as expensive, or
more expensive, than laboratory testing. A strong em-
phasis needs to be placed on innovative strategies to en-
sure quality for tests that are being conducted in volumes
far beyond that covered by conventional laboratory quality
assurance plans and accreditation status. In South Africa,
there is an ISO standard (ISO22789) that has been imple-
mented for accredited laboratories to follow if they are
conducting and supporting POC testing [38]. Perhaps
a similar approach to accreditation of clinic sites con-
ducting POC testing with a simpler standard and checklist
could be used to ensure quality is maintained in field-
testing sites.
The pipeline for HIV diagnosis and monitoring
There is an ever-expanding pipeline associated with the
strong advocacy for POCT from global players, who main-
tain that universal access for HIV and TB care requires
the use of POCT for earlier testing and improved re-
tention in care. Cited advantages of POCT include im-
proved turnaround time, greater accessibility, potentially
improved patient retention and possible reduction in over-
all healthcare costs. However, despite the rapid growth
and interest in POCT, many aspects remain controversial,
in part because this approach challenges the conventional
approach to laboratory testing, which remains the prevail-
ing paradigm in many countries. In addition, while nu-
merous early or near market entry products are available,
at the time of writing few could be purchased on a large
scale, outside of rapid HIV and malaria strip-based tests,
and a monopoly exists of one or two suppliers with a
proven track record for CD4 testing, such as the PIMA
assay (Alere Inc., Waltham, MA, USA). In the VL arena,
many early market entry products are available and devel-
opment has been heavily funded, yet only three were avail-
able for clinical validation as of April 2014 - the LIAT™
Analyzer (IQuum, Inc., Roche) [39], Alere™ q HIV-1/2
Detect (Alere) [40] and Samba (Diagnostics for the
Real-World, Ltd.) [41] - and manufacturing track records
for scale-up were not available. The upcoming pipeline
for HIV CD4 and VL testing with their performance
characteristics are summarized in the landscape document
produced annually by UNITAID [12]. A plethora of fast
followers are in various stages of research, development
and evaluation and include the MBio POC CD4 (MBio
Diagnostics, Inc)(Co,USA) [42], Daktari CD4 Counter
(Daktari Diagnostics, Inc.)(MA, USA), FACSPresto™ (BD
Biosciences)(NJ, USA) [43], Visitect® (Omega Diagnostics),
Zyomyx CD4 (Zyomyx, Inc.) and EMD Millipore® Muse™
(Merck)(Darmstadt,Germany) [12]. For VL testing, these
include the GeneXpert® Viral Load system (Cepheid,
Sweden), the EOSCAPE-HIV™ Rapid RNA Assay system
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Time micro PCR system (MolBio Diagnostics, Ltd.),
Goa, India Savanna VL test and platform (Northwestern
Global Health Foundation in collaboration with Quidel
Corporation) and Bioluminescent Assay in Real Time tech-
nology (Lumora, Ltd.)(cambridgeshire,UK) [45], amongst
others [12].
In countries where significant laboratory infrastructure
currently exists in both the public and private sectors,
the sheer volumes of testing may make total decentra-
lization prohibitive in terms of instrumentation and
human resource requirements. In these instances, POC
assays may and do have a role to play where gaps in
service are noted, which can be identified by approaches
such as geographic information systems mapping to en-
sure a national ‘total coverage model’. The total coverage
model is a new term being used in laboratory testing cir-
cles which refers to a tiered implementation model that
includes both POC testing and different tiers of labora-
tory testing to ensure access for the entire national po-
pulation. POCTs are also used heavily in specific niche
areas such as hemoglobin in emergency rooms or renal
clinics. A particular niche for the VL assay could, for ex-
ample, be in maternity wards and antenatal care clinics
where pregnant women infected with HIV could be
monitored for risk of transmission and success of treat-
ment strategies, and exposed infants could be tested at
birth for HIV and then treatment initiated as soon as
possible.
Major issues surrounding the implementation of POCT
exist and include poor regulatory control, difficulties in
ongoing monitoring of quality, and limited availability of
guideline documents for the safe implementation of POC
devices. In addition, there are few studies that report data
on full economic costing for POC [46], which is likely to
vary depending on tests used, diseases investigated and
model input parameters.
There is a dearth of well-designed randomized
controlled clinical trials (RCTs) to evaluate the outcomes
and impact of the implementation of POCT. Most
notable for their contributions to the POC literature are
a group led by Shephard in Australia [47,48]. Although
evaluating other assays in a general practitioner setting
in Australia, the final study conclusions were that POCT
was not inferior to laboratory-based testing, but came at
a substantially higher cost that needs to be weighed
against overall health benefits. Various clinical experi-
ences were presented at a recent forum held in South
Africa, with a number of studies reporting progress in
RCT studies such as the Home-based Care Plus trial in
Kwazulu-Natal, Rapid Initiation of Anti-retrovirals in
Pregnancy (RAP) study in Cape Town, the Grand Chal-
lenges Canada RCT, and RapIT (Midrand PHC, South
Africa). Results are still awaited eagerly and will helpform policy but have shown clearly that POCT is just
one step in a multi-step process along the continuum of
care [49]. Other experiences show that POCT has great
potential for certain high-risk populations such as mi-
grants or adolescents where loss to follow-up is high and
where immediate results would add value [49].
Pilot studies on the implementation of PIMA CD4
POC testing in South Africa and Mozambique have
demonstrated that time to initiation is reduced; however,
challenges were identified in that nurses perceived POC
implementation as additional workload, and patients
migrated from facilities before staff were able to track,
record and file the results in patients’ folders [49]. Expe-
riences from Mozambique showed that after the intro-
duction of POC CD4, the loss to follow-up before CD4
staging dropped, ART initiation rate increased, and time
to ART initiation was reduced from 48 days to 20 days
[50]. Retention rates in care, however, remained the
same. It was recommended by this group that deploying
POC should be done in in conjunction with conven-
tional testing as part of a total laboratory network and
there was acknowledgement that POC testing is far from
error-proof. Only 20% of Mozambique’s CD4 counts are
conducted at POC. High invalid rates were noted using
POC CD4 tests in this study. The authors warned that
simple implementation is not always efficient - access
does not necessarily mean that the patient gets care
(approximately 25% of patients did not get CD4 testing
even with POCT on site). They also highlighted that
significant health systems strengthening is needed and
clinic workflow re-engineering. A meta-analysis of the
performance of PIMA is underway and preliminary
analysis have revealed that the performance of the in-
strument on venous specimens is as good as current
gold standard technology. However, the performance
on capillary-derived specimens showed increased vari-
ability at the 350 cells/μl threshold, resulting in higher
false-positive rates that would lead to more patients being
placed on ART (unpublished results, Lesley Scott personal
communication).
Approaches to ensuring quality testing
The US Food and Drug Administration requirements for
defining a simple test are that it should be rapid, easy to
perform, require minimal training and no specialized
laboratory setup, and reagents should be stable and tem-
perature independent. However, few assays actually meet
these requirements. It should be noted that assay trans-
fer from the laboratory to POC is not synonymous with
improved quality of care. Implementation at the POC
will require facilitation in a step-wise fashion with care-
ful monitoring and evaluation at each step. The approach
to quality of rapid lateral flow-based assays will be diffe-
rent to those that are device based. Several guidelines for
Stevens et al. BMC Medicine 2014, 12:173 Page 5 of 8
http://www.biomedcentral.com/1741-7015/12/173HIV rapid testing have been written over the years, but
uptake of these recommendations has been poor in
most resource-limited settings. In fact, many of these
assays are considered Clinical Laboratory Improvement
Amendment-waived because they are simple tests with
a low risk for an incorrect result and are thus not
quality assured in developed countries such as the USA.
While programs such as the WHO pre-qualification
process [51] have provided guidance by conducting
product and supplier evaluations and validations, and
the Centers for Disease Control and Prevention (CDC)
has done similar work for PEPFAR-related programs,
there is a need for harmonization of approaches and stan-
dardization of protocols with greater co-operation be-
tween stakeholders. There needs to be co-ordination
between and a review of all strategies and guidelines
so that a simple, single guidance can be provided for
countries. Quality needs to be addressed, within the
laboratory and at the pre-analytic, analytical and post-
analytical phases [22]. For rapid assays, the sheer vol-
umes of assays conducted make conventional internal
and external quality approaches extremely difficult to
implement. Strategies employed have included the use
of external quality assurance (EQA) material using dried
tube spots for various HIV rapid assays [52] or dried
culture spots for near POCT for TB [53,54]. Innovative
strategies are required for material distribution and data
collection across large programs. Regular training and
re-training, competency assessments, and ongoing super-
vision and mentoring of staff conducting assays are all
critical to ensuring continuous maintenance of quality.
For device-based assays, an approach that is under
scrutiny is the use of real-time continuous monitoring
using various connectivity systems linked to analyzers in
the field [55,56]. Connectivity provides a means not only
to ensure analyzer performance meets requirements, but
also of collecting programmatic data, distribution of re-
sults and identifying the need to intervene should prob-
lems arise. Data ownership and data security are issues
that need to be addressed. Each analyzer, however, fre-
quently connects to the middleware or software solution
via a different mechanism and there is thus a need for
industry standards for POCT connectivity [57]. Several
middleware programs have been evaluated that link to
laboratory information systems in South Africa with
success, although approaches differ in different regions
depending on wireless availability, internet access and
computer literacy. Thus solutions may need to be con-
textualized within different geographic regions. Simpler
approaches may include the use of bi-directional short
message service printers with additional capabilities
for data collection and acknowledgement of receipt of
results [58]. To improve retention in care, patients can
be recalled for results, and this makes for a reasonablysuccessful means of improving adherence [59]. The role
of secondary and tertiary laboratories in the management
of quality in PHCs is essential and many believe POCT
should be a natural extension of the laboratory [60].
Supply chain management and procurement strategies
need to be well planned. Global procurement and global
forecasting may play a larger role than for other assays
because the production lines for new assays entering the
market are frequently unable to meet the demand of
rapid recommendations that lead to rapid global uptake.
Engagement with industry in the pre-market phase may
help to ensure quality features are built into the system,
connectivity is considered, and production meets the
needs based on information provided on disease preva-
lence and likely test numbers. UNITAID, as an organiza-
tion that funds approaches to catalyze and effect market
changes, can stimulate additional approaches improving
access. Advocacy for quality assured, appropriately
selected assays used in settings where impact can be
demonstrated is strongly needed.
Ownership and accountability
There is a general consensus that ownership should be
at the level of in-country ministries of health. A POCT
policy needs to be embedded within national strategic
laboratory plans, the development of which was strongly
advocated for by the Maputo declaration [61]. A single
strategic national plan for the introduction of POCT in
a country is likely to solicit donor funding or that of
local treasuries in a far more effective manner. It is
imperative that technical task teams are established to
support decision making. The composition of the team
should include clinicians; laboratorians; health econo-
mists; procurement, supply and distribution workers;
and funders. Strong partnerships with industry need to
be facilitated because the ongoing procurement, main-
tenance of analyzers and product failures need to be
addressed. As a result of recent product failures in the
HIV arena impacting many countries, a task team was
established with expertise from organizations such as
the WHO, CDC and other partners. This may be useful
going forward to urgently address product failures as
this body is formalized. This brings in the concept of a
far more active reporting to support post-market sur-
veillance, currently poorly coordinated the world over.
Ownership of the POCT process, however, needs to
extend to users of the assays and the communities that
are tested, with creative ways developed for incentiviz-
ing healthcare workers conducting the tests to maintain
high quality standards.
Conclusions
POCT will improve access to needed HIV and associated
diagnostics, but these assays are not without limitations
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tegrate these technologies cost-effectively and efficiently
into clinical algorithms and existing laboratory networks.
In costing, it should be emphasized that context matters,
particularly human resources and test volumes. There is
much to be done in this field. Notably, large randomized
studies measuring the impact of a diagnostic interven-
tion along the entire continuum of care are currently an
exception and need to be encouraged and supported.
Standardization of assay evaluation and development of
appropriate internal and external quality control are im-
portant activities that need support. Regulatory hurdles
need to be overcome and developed in many countries.
Global harmonization of all stakeholder activities is es-
sential to get the product from an idea to the bench and
ultimately to the patient bedside. The likelihood is that
in many countries POCT will be strategically deployed
in a hybrid model with support from the conventional
tiers of in-country laboratories.
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